The Canadian Society for Vascular Surgery (CSVS) has released a list of specific tests, treatments or procedures that are commonly ordered but not always necessary in vascular surgery as part of the Choosing Wisely Canada campaign. The list identifies five targeted, evidence-based recommendations that can support conversations between patients and physicians about what care is really necessary.
For years, the radiology industry has focused on reducing, or eliminating patient exposure to radiation. Recently, the industry has shifted attention to the cumulative effect radiation exposure has over the course of a physician’s career.
Twelve-month data from the EXCITE ISR clinical trial were presented by Craig Walker at New Cardiovascular Horizons (NCVH; 27–29 May, New Orleans, USA). Results of the study show that Spectranetics’ laser atherectomy devices used with balloon angioplasty, are safer and more effective than angioplasty alone for treating femoropopliteal in-stent restenosis, demonstrating continued durability in 12-month results.
Presented for the first time at EuroPCR 2015 (19–22 May, Paris, France) during the “Hot line” session on peripheral interventions, new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic successfully treated long lesions in the superficial femoral and popliteal arteries.
Shockwave Medical has announced US$40m in funding, co-led by returning investor Sofinnova Partners and new investor Venrock, with the participation of RA Capital, Deerfield, Sectoral Asset Management, Ally - See more at: h
Silk Road Medical has announced that the company has received premarket approval (PMA) from the US Food & Drug Administration (FDA) for the Enroute transcarotid stent system. The Enroute transcarotid stent is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe and more direct approach to carotid artery stenting.
Nitiloop has received FDA clearance for its first product, NovaCross, which is intended to be used in conjunction with a guidewire to access discrete regions of the coronary or peripheral vasculature.
The abstract, published by the American Society for Clinical Oncology (ASCO) as part of the 2015 annual meeting abstracts released on its website, reveals that Sirtex’s SIRFLOX study of 530 patients revealed median progression-free survival (PFS) in the liver of 20.5 months, an improvement of 7.9 months over the current standard chemotherapy plus Avastin.
In the past five years we have treated more than 400 patients for uterine fibroids, bone metastasis and osteoid osteoma in routine practice with significant clinical results and negligible adverse events, but therapeutic ultrasound still has some technological hurdles that need to be overcome, writes Alessandro Napoli.
A rapid overview of three of these treatments: ablation, chemoembolization and selective interval radiation therapy, should help clarify the challenges and difficulties of determining tumour response in interventional oncology, write Maxime Ronot and Valérie Vilgrain.
Hansen has announced the completion of the world’s first clinical procedure with the Magellan 10F robotic catheter. Interventional radiologist Gerard Goh performed the procedure at The Alfred Hospital in Melbourne, Australia. He used the 10F catheter during a robot-assisted placement of an inferior vena cava filter.
Lombard Medical has announced the enrolment and treatment of the first patient in the ARCHYTAS global registry. An 89-year-old male with a 64mm aneurysm and challenging 75-degree aortic neck angulation was treated with Lombard Medical’s Aorfix endovascular stent graft in Girona, Spain.
EndoShape has announced that it has been selected to present at the Cavendish Global Health Impact Forum taking place 10–14 May in La Jolla, USA.
Quiremspheres, that were developed by the University Medical Center (UMC) Utrecht, The Netherlands, to be used in a new treatment for liver cancer, have received the European CE mark for quality and safety. The treatment is being marketed by Quirem Medical, a spin-off company of the UMC Utrecht.
Surefire Medical has announced that the company’s new Precision targeted delivery infusion system, for direct-to-tumour embolization procedures, has received the CE mark from European regulators. Surefire infusion systems are today used primarily in treating inoperable liver cancers, although clinical trials are under way for additional medical conditions.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos